Efficacy and safety of rVIII-Singlechain: Results of a phase 1/3 multicenter clinical trial in severe hemophilia A

Blood

Volumn 128, Issue 5, 2016, Pages 630-637

  Mahlangu, Johnny ^a   Kuliczkowski, Kazimierz ^b   Karim, Faraizah Abdul ^c   Stasyshyn, Oleksandra ^d   Kosinova, Marina V ^e   Lepatan, Lynda Mae ^f   Skotnicki, Aleksander ^g   Boggio, Lisa N ^h   Klamroth, Robert ⁱ   Oldenburg, Johannes ^j   Hellmann, Andrzej ^k   Santagostino, Elena ^l   Baker, Ross I ^m   Fischer, Kathelijn ⁿ   Gill, Joan C ^o   P'Ng, Stephanie ^p   Chowdary, Pratima ^q   Escobar, Miguel A ^r   Khayat, Claudia Djambas ^s   Rusen, Luminita ^t   Bensen Kennedy, Debra ^u   Blackman, Nicole ^u   Limsakun, Tharin ^u   Veldman, Alex ^v   Ledger, Katie St ^u   Pabinger, Ingrid ^w   more..

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c National Blood Centre   (Malaysia)

^d STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

^e Kemerovo Regional Clinical Psychiatric Hospital   (Russian Federation)

^f Perpetual Succour Hospital   (Philippines)

^g Krakowskie Centrum Medyczne   (Poland)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

ⁱ Department of Dermatology and Phlebology   (Germany)

^j UNIVERSITY HOSPITAL BONN   (Germany)

^k MEDICAL UNIVERSITY OF GDANSK   (Poland)

^l FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^m MURDOCH UNIVERSITY   (Australia)

ⁿ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^o BLOOD RESEARCH INSTITUTE   (United States)

^p ROYAL PERTH HOSPITAL   (Australia)

^q ROYAL FREE HOSPITAL   (United Kingdom)

^r UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^s SAINT JOSEPH UNIVERSITY   (Lebanon)

^t SC SANADOR SRL   (Romania)

^u CSL BEHRING   (United States)

^v CSL BEHRING GMBH   (Germany)

^w MEDICAL UNIVERSITY OF VIENNA   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8 SINGLECHAIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 8; RECOMBINANT PROTEIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BINDING AFFINITY; BLOOD CLOTTING; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HEMOPHILIA A; HEMOSTASIS; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MULTICENTER STUDY; MULTIPLE DRUG DOSE; OPEN STUDY; OPTIMAL DRUG DOSE; PERIOPERATIVE PERIOD; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; REPEATED DRUG DOSE; RHINOPHARYNGITIS; SINGLE DRUG DOSE; VOLUME OF DISTRIBUTION AT STEADY-STATE; ADOLESCENT; CLINICAL TRIAL; DEMOGRAPHY; DOSE RESPONSE; DRUG EFFECTS; HEMORRHAGE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; CHILD; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84983000332     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-01-687434     Document Type: Article

References (23)

1. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; Treatment Guidelines Working Group on Behalf of The World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-e47.
2. Schaub RG. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia. Biochem Pharmacol. 2011;82(2):91-98.
3. Ragni MV. New and emerging agents for the treatment of hemophilia: focus on extended halflife recombinant clotting proteins. Drugs. 2015; 75(14):1587-1600.
4. De Moerloose P, Urbancik W, Van Den Berg HM, Richards M. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia. 2008;14(5):931-938.
5. Duncan N, Shapiro A, Ye X, Epstein J, Luo MP. Treatment patterns, health-related quality of life and adherence to prophylaxis among haemophilia A patients in the United States. Haemophilia. 2012;18(5):760-765.
6. Konkle BA, Stasyshyn O, Chowdary P, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015;126(9): 1078-1085.
7. Mahlangu J, Powell JS, Ragni MV, et al; A-LONG Investigators. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123(3):317-325.
8. Kepa S, Horvath B, Reitter-Pfoertner S, et al. Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A. Haemophilia. 2015;21(3):343-350.
9. Dasgupta S, Repessé Y, Bayry J, et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood. 2007;109(2):610-612.
10. Delignat S, Repessé Y, Navarrete AM, et al. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A. Haemophilia. 2012;18(2):248-254.
11. Zollner SB, Raquet E, Müller-Cohrs J, et al. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII. Thromb Res. 2013;132(2):280-287.
12. Klamroth R, Simpson M, Von Depka-Prondzinski M, et al. Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate ® )in patients with severe haemophilia A. Haemophilia. 2016; in press.
13. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194.
14. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost. 1995;73(2):247-251.
15. Lentz SR, Misgav M, Ozelo M, et al. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia. 2013;19(5):691-697.
16. Lissitchkov T, Hampton K, von Depka M, et al. Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq ® ) in adults with severe haemophilia A: efficacy and safety [published online ahead of print August 28, 2015]. Haemophilia. doi: 10.1111/hae.12793.
17. Valentino LA, Negrier C, Kohla G, et al. The first recombinant FVIII produced in human cells-an update on its clinical development programme. Haemophilia. 2014;20(suppl 1):1-9.
18. Tarantino MD, Collins PW, Hay CR, et al; RAHF-PFM Clinical Study Group. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia. 2004;10(5): 428-437.
19. Recht M, Nemes L, Matysiak M, et al. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia. 2009;15(4): 869-880.
20. Santagostino E, Lentz SR, Misgav M, et al. Safety and efficacy of turoctocog alfa (NovoEight ®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials. Haemophilia. 2015;21(1):34-40.
21. Shapiro AD, Ragni MV, Kulkarni R, et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost. 2014;12(11): 1788-1800.
22. Batlle J, Gómez E, Rendal E, et al. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects. Ann Hematol. 1996;72(5): 321-326.
23. Klintman J, Hillarp A, Berntorp E, Astermark J. Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy. Br J Haematol. 2013;163(3):385-392.